FDA allows emergency use of drug for coronavirus
WASHINGTON — U.S. regulators on Friday allowed emergency use of an experimental drug that appears to help some coronavirus patients recover faster.
It is the first drug shown to help fight COVID-19, which has killed more than 230,000 people worldwide.
The Food and Drug Administration acted after preliminary results from a government-sponsored study showed that Gilead Sciences’ remdesivir shortened the time to recovery by 31%, or about four days on average, for hospitalized COVID-19 patients.
The study of 1,063 patients is the largest and strictest test of the drug and included a comparison group that received just usual care so remdesivir’s effects could be rigorously evaluated.
President Donald Trump announced the FDA’s action at the White House.
Those given the drug were able to leave the hospital in 11 days on average versus 15 days for the comparison group. The drug also might be reducing deaths, although that’s not certain from the partial results revealed so far.
In a clinical trial, the drug remdesivir shortened recovery time for patients with advanced cases of COVID-19, the disease caused by the coronavirus.
The National Institutes of Health’s Dr. Anthony Fauci said the drug would become a new standard of care for severely ill COVID-19 patients like those in this study. The drug has not been tested on people with milder illness. It currently is given through an IV in a hospital.
Gilead has said it would donate its available stock of the drug and is ramping up production to make more.
No drugs are approved now for treating the coronavirus, and remdesivir will still need formal approval.
The FDA previously gave emergency-use authorization to a malaria drug, hydroxychloroquine, after President Donald Trump repeatedly promoted it as a possible treatment for COVID-19. No large high-quality studies have shown the drug to work for that, however, and it has significant safety concerns.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
